US Patent

US11129833 — Methotrexate formulation

Formulation · Assigned to Therakind Ltd · Expires 2035-10-28 · 9y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a liquid pharmaceutical composition containing methotrexate free acid and a buffer, with a pH range of 6.5 to 8.2.

USPTO Abstract

A liquid pharmaceutical composition comprises methotrexate free acid and a buffer, wherein the pH of the composition is in the range of 6.5 to 8.2. Processes for preparation of the liquid pharmaceutical composition are also described. The liquid pharmaceutical composition is useful in therapy.

Drugs covered by this patent

Patent Metadata

Patent number
US11129833
Jurisdiction
US
Classification
Formulation
Expires
2035-10-28
Drug substance claim
No
Drug product claim
Yes
Assignee
Therakind Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.